Trials / Terminated
TerminatedNCT00997152
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of JTT-654 Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of JTT-654 on diabetes as well as the safety, tolerability and pharmacokinetics of JTT-654 in type 2 diabetic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTT-654 | Tablets |
| DRUG | JTT-654 Placebo | Tablets |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-03-01
- Completion
- 2010-04-01
- First posted
- 2009-10-19
- Last updated
- 2013-02-04
Locations
42 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00997152. Inclusion in this directory is not an endorsement.